Scholarlink

Purpose of Review <p>We aim to review rapidly evolving data regarding clinical benefits of cardiac myosin inhibition in obstructive and non-obstructive hypertrophic cardiomyopathy (HCM).</p> Recent Findings <p>Both EXPLORER-HCM and VALOR-HCM have demonstrated a long-term clinical benefit from mavacamten in decreasing New York Heart Association (NYHA) class and degree of left ventricular outflow tract (LVOT) obstruction with a good safety profile, and potential for favorable long term myocardial remodeling. Similarly SEQUOIA-HCM and MAPLE-HCM demonstrated aficamten significantly decreased LVOT obstruction and symptoms and was more effective than standard medical therapy in improving exercise capacity and decreasing symptoms. Mavacamten (ODYSSEY‑HCM)) did not lead to significant clinical improvement in nonobstructive HCM. For aficamten, randomized evidence in non-obstructive HCM is still accruing.</p> Summary <p>While there is strong evidence in favor of cardiac myosin inhibition in obstructive HCM, our understanding of the potential impact on long-term remodeling, and in heterogenous non-obstructive HCM is still developing. Better understanding of the impact of long-term remodeling and factors that modulate drug efficacy will further guide our use of these medications. </p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Update: Cardiac Myosin Inhibitors in Obstructive and Non-obstructive Hypertrophic Cardiomyopathy

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年4月28日

查看全文
  • Jay Ramchand,
  • Jeffrey Bennett

摘要

Purpose of Review

We aim to review rapidly evolving data regarding clinical benefits of cardiac myosin inhibition in obstructive and non-obstructive hypertrophic cardiomyopathy (HCM).

Recent Findings

Both EXPLORER-HCM and VALOR-HCM have demonstrated a long-term clinical benefit from mavacamten in decreasing New York Heart Association (NYHA) class and degree of left ventricular outflow tract (LVOT) obstruction with a good safety profile, and potential for favorable long term myocardial remodeling. Similarly SEQUOIA-HCM and MAPLE-HCM demonstrated aficamten significantly decreased LVOT obstruction and symptoms and was more effective than standard medical therapy in improving exercise capacity and decreasing symptoms. Mavacamten (ODYSSEY‑HCM)) did not lead to significant clinical improvement in nonobstructive HCM. For aficamten, randomized evidence in non-obstructive HCM is still accruing.

Summary

While there is strong evidence in favor of cardiac myosin inhibition in obstructive HCM, our understanding of the potential impact on long-term remodeling, and in heterogenous non-obstructive HCM is still developing. Better understanding of the impact of long-term remodeling and factors that modulate drug efficacy will further guide our use of these medications.